KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108.

Fred Saad, Paula Del Rosario, Noel W Clarke

Eur Urol 85(6) e178-e179

PMID38042647
PMCID-
DOI10.1016/j.eururo.2023.11.015
发表日期2023-12-02
摘要

摘要

无摘要

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。